Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISTOCRAT: Sativex plus temozolomide for recurrent glioblastoma
ISRCTN11460478Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Feb 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Sativex + temozolomide with Placebo + temozolomide (2 arms). Primary endpoint: Overall survival. Started Feb 2023; status: active, not recruiting.
02
Drugs
cannabidioltemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN11460478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11460478.